COMUNICADO: Enbrel(R) Shown to Deliver Long-Lasting Improvements in Psoriasis Patients' Quality of Life (y 2)

Actualizado 18/09/2008 15:05:19 CET

Health-related quality of life (HRQoL) refers to a person or group's perceived physical and mental health over time, and is used to better understand how an illness interferes with a person's day-to-day life.

-- EuroQOL-5D (EQ-5D) questionnaire measures HRQoL and evaluates 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The severity of impairment for each dimension is rated as "no problem," "some problem," and "extreme problem."

-- Dermatology Life Quality Index (DLQI) is a compact self-reported questionnaire to measure HRQoL over time in patients with skin diseases. It consists of 10 items covering symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Each item is scored on a four point scale, with higher scores indicating greater impairment in HRQoL.

Advances in Psoriasis Research Awards

The Advances in Psoriasis Research Grant Programme was launched by Wyeth Pharmaceuticals on 29 October 2007 to mark World Psoriasis Day 2007. The programme this year was open to researchers in Europe, the Middle East and Africa, and offered six lab-based or clinical investigators the opportunity to receive a EURO 100,000 grant to support high-quality and innovative research into the inflammatory pathogenesis of psoriasis and TNF-related skin disorders.

All applications were judged by an expert panel of international leaders in dermatology and grants were awarded on the basis of robust scientific rationale, combined with the potential advancements that may be achieved in the understanding of the mechanism of psoriasis and related conditions. The Awards further reinforce Wyeth's commitment to the study of psoriasis, the development of optimal treatments for skin clearance and overall improvements in patients' quality of life.

For further information please visit:

About Enbrel(5)

Enbrel is a fully human soluble tumour necrosis factor (TNF) receptor antagonist. Enbrel was first approved in 1998 for moderate to rheumatoid arthritis and has since been used in nearly 500,000 patients worldwide across indications.

Enbrel in the EU is approved for the following indications:

Rheumatoid arthritis

Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate. Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.

Polyarticular juvenile idiopathic arthritis

Treatment of active polyarticular juvenile idiopathic arthritis (JIA) in children and adolescents aged 4 to 17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children aged less than 4 years.

Psoriatic arthritis

Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

Ankylosing spondylitis

Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

Plaque psoriasis

Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA. The European Commission recently approved a new 50mg Enbrel once-weekly dosage regimen as an alternative to the currently approved 25mg Enbrel twice-weekly regimen for the treatment of patients with moderate-to-severe plaque psoriasis.

About Wyeth:

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, haemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


1. Poster FP 1465 from the European Association for Dermatology and Venereology Congress, September 2008. Cardoso, J. et al. Both continuous and intermittent etanercept therapy improve health-related quality of life in patients with moderate-to-severe psoriasis

2. Poster FP1359 from the European Association for Dermatology and Venereology Congress, September 2008. Lambert, J. et al. Sustained improvements in depression and anxiety symptoms with etanercept therapy for up to 54 weeks in patients with moderate to severe psoriasis: results of the CRYSTEL study

3. Poster FP 1391 from the European Association for Dermatology and Venereology Congress, September 2008. Peyri, J. et al. Effect of etanercept on joint pain in patients with moderate-to-severe psoriasis: intermittent versus continuous dose regimens

4. Van de Kerkhof, PCM. et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. British Journal of Dermatology, published online: 31 July 2008.

5. Enbrel EMEA SPC

For further information, please contact: Wyeth: Gill Markham, Communications, Tel: +44-777-082-7753, Email: Danielle Halstrom, Communications, Global, Europe, Middle East and Africa, Tel: +1-215-280-3898, Email: OgilvyHealthPR: Mary Barrington-Ward, Tel: +44-207-108-6066, Email: Nerea Hinzpeter, Tel: +1-646-407-9015, Email:

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación